# Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma

> **NCT02482532** · PHASE1 · COMPLETED · sponsor: **Gary Doolittle** · enrollment: 7 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** tvs-CTL Vaccine

## Key facts

- **NCT ID:** NCT02482532
- **Lead sponsor:** Gary Doolittle
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-06
- **Primary completion:** 2019-10-10
- **Final completion:** 2021-09-13
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2022-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02482532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02482532, "Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02482532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*